Taysha Gene Therapies (TSHA) EBIT Margin (2021 - 2025)
Taysha Gene Therapies (TSHA) reported EBIT Margin of -515.95% for Q4 2025, up 469.80 percentage points from -985.76% a year earlier.
Powered by 
Analysis
Taysha Gene Therapies (TSHA) EBIT Margin (2021 - 2025) Analysis & Trends
For FY2025, Taysha Gene Therapies posted EBIT Margin of -1130.65%, down 33.09 percentage points from FY2024.
- EBIT Margin has a three-year change of +5362.04 percentage points (FY2022 to FY2025).
- By year, EBIT Margin came in at -1097.55% in FY2024 (-628.72 pp), -468.83% in FY2023 (+6023.86 pp) and -6492.69% in FY2022.
- The Q4 2025 figure ranks as the highest quarterly EBIT Margin since Q4 2023.
- Year over year, EBIT Margin gained in two of the last seven quarters, with an average year-over-year change of -302.94 percentage points.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,165.22 Bn | 1,133.81 Bn | 19.71 Bn | 51.16% |
| 2 | Johnson & Johnson | 646.28 Bn | 566.14 Bn | 17.30 Bn | 24.35% |
| 3 | AbbVie | 503.17 Bn | 476.28 Bn | 12.70 Bn | 37.86% |
| 4 | Merck | 365.23 Bn | 319.60 Bn | 12.21 Bn | -3.52% |
| 5 | Novartis Ag | 302.66 Bn | 266.65 Bn | 11.24 Bn | 32.97% |
| 6 | Astrazeneca | 267.39 Bn | 241.08 Bn | 12.86 Bn | 20.57% |
| 7 | Amgen | 241.61 Bn | 197.01 Bn | 7.24 Bn | 34.95% |
| 8 | Gilead Sciences | 194.67 Bn | 168.86 Bn | 6.22 Bn | -133.21% |
| 9 | Pfizer | 172.91 Bn | 119.55 Bn | 10.94 Bn | 28.37% |
| 10 | Taysha Gene Therapies | 1.46 Bn | 106.76 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -515.95% |
| Jun 30, 2025 | -1,347.08% |
| Mar 31, 2025 | -930.54% |
| Dec 31, 2024 | -985.76% |
| Sep 30, 2024 | -1,448.43% |
| Jun 30, 2024 | -1,915.38% |
| Mar 31, 2024 | -713.28% |
| Dec 31, 2023 | -450.78% |
| Sep 30, 2023 | -342.39% |
| Jun 30, 2023 | -976.37% |
| Mar 31, 2023 | -351.87% |
| Dec 31, 2022 | -27,118.59% |
| Sep 30, 2022 | -282,855.56% |
| Jun 30, 2022 | -123,603.70% |
| Mar 31, 2022 | -354,650.00% |
| Dec 31, 2021 | -171,462.07% |
| Sep 30, 2021 | -136,975.68% |
| Jun 30, 2021 | -101,930.00% |
| Mar 31, 2021 | -48,621.21% |
API Access
Taysha Gene Therapies EBIT Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebit-margin&ticker=TSHA&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebit-margin", "ticker": "TSHA", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebit-margin&ticker=TSHA&period=max&api_key=YOUR_API_KEY");
const data = await res.json();